Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Frequently asked questions
What sector does Vicore Pharma Holding AB (publ) (VICO) operate in?
Vicore Pharma Holding AB (publ) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Vicore Pharma Holding AB (publ) (VICO) current stock price?
As of the latest data, Vicore Pharma Holding AB (publ) stock price is SEK 11.68, with a previous close of SEK 11.74. Vicore Pharma Holding AB (publ) lost -SEK 0.06 in the last trading session, representing a -0.51% loss.
What is Vicore Pharma Holding AB (publ) (VICO) current market capitalization?
Vicore Pharma Holding AB (publ) market cap is approximately 3.29 billion.
What is Vicore Pharma Holding AB (publ) (VICO) Earnings Per Share (EPS)?
The trailing EPS is -SEK 1.90, and the forward EPS is -SEK 1.47.
What is Vicore Pharma Holding AB (publ) (VICO) EBITDA?
Vicore Pharma Holding AB (publ) EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -123.50 million.
Does Vicore Pharma Holding AB (publ) (VICO) pay dividends?
No. Vicore Pharma Holding AB (publ) does not pay a dividend.
How did Vicore Pharma Holding AB (publ) (VICO) perform in its most recent earnings report?
In the last report (March 31, 2026), Vicore Pharma Holding AB (publ) posted an EPS surprise of 18.75% and a revenue surprise of 26.21%.
When is Vicore Pharma Holding AB (publ) (VICO) next earnings report?
Vicore Pharma Holding AB (publ) is expected to release its next earnings report on June 30, 2026.
What is Vicore Pharma Holding AB (publ) (VICO) beta (volatility) score?
Vicore Pharma Holding AB (publ) has a beta of 0.149, indicating lower volatility than the overall market.
